Weekly Recap: Phase 3 set for efzofitimod and 60% staff cut, $58.9M cash

aTyr Pharma, Inc. (NASDAQ:ATYR) won FDA alignment for a Phase 3 efzofitimod trial in pulmonary sarcoidosis—54 weeks, ~372 patients with FVC at week 48 primary—and despite a ~60% staff cut and shares near $0.35, it holds $58.9M to fund operations into late 2028.Previous Week RecapThis is an AI-gener…